CompletedNCT01161277
Aripiprazole and Haloperidol Effects on Brain Activity
About this title
Read the official source — NCT01161277Medication studyAges 18–50NorwaySchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 50 years.
- Listed locations
- OsloSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateAugust 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 54
- Sponsor
- Oslo University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Norway
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01161277
- Official title
Show the full official title
Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning: A Pharmacological fMRI Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Oslo
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Oslo University Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole, Haloperidol and Placebo sugar pill.
Who was this study for?
Listed age limits: 18 years to 50 years.
